ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IQAI Iq-ai Limited

1.50
0.00 (0.00%)
16 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Iq-ai Limited LSE:IQAI London Ordinary Share JE00BD4H0R42 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.50 1.40 1.60 1.50 1.50 1.50 413,646 07:42:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Florists 536k -512k -0.0028 -5.36 2.74M

IQ-AI Limited IB Software Chosen by LA County Hospital (8017A)

04/06/2021 7:00am

UK Regulatory


Iq-ai (LSE:IQAI)
Historical Stock Chart


From Apr 2021 to Apr 2024

Click Here for more Iq-ai Charts.

TIDMIQAI

RNS Number : 8017A

IQ-AI Limited

04 June 2021

4 June 2021

IQ-AI Ltd

("IQ-AI" or the "Company")

IB Software Chosen by LA County Hospital

Imaging Biometrics(R), LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), announced today that Los Angeles County Hospital (LAC) has purchased IB Clinic. Following the recent installation at the Keck Medical Center of USC, the purchase further extends IB's exclusive quantitative imaging capabilities throughout the entire USC and LA County Hospital network; the hub in the County-run healthcare system which serves over 10 million residents.

The automated generation of IB's quantitative parameter maps are ideal for high-volume brain tumour centers such as USC/LAC. Within seconds after acquiring the MR data from the scanner, IB's quantitative output is available for diagnostic review. The unattended processing offloads busy radiology departments, including MR technologists and neuro radiologists, and fosters more productive workflows. More importantly, the standardised output of IB's software is independent of scanner, field strength, patient or timepoint. Therefore, direct comparison of tumour volumes can be made regardless of when or where a patient is scanned.

Another ancillary benefit of IB's brain tumour imaging platform is that it helps drive a more consistent language for the entire treatment team. The quantitative output provides objective and consistent terminology that is shared by radiologists, oncologists, surgeons, and the patients they serve.

"IB has been in the center of long-standing collaborative efforts focused on standardising the acquisition and post-processing of brain tumour imaging protocols across healthcare. This purchase by LAC underscores the progress made towards this goal, and we look forward to working with other cancer centers interested in our approach," said Michael Schmainda, CEO of IB.

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

 
 IQ-AI Limited 
  Trevor Brown/Vinod Kaushal/Qu Li 
  Tel: 020 7469 0930 
---------------------------------------------------------- 
 Peterhouse Capital Limited (Financial Adviser and Broker) 
  Lucy Williams/Mark Anwyl 
  Tel: 020 7220 9797 
---------------------------------------------------------- 
 

ABOUT Imaging Biometrics , LLC

Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDFLFEDRFIVIIL

(END) Dow Jones Newswires

June 04, 2021 02:00 ET (06:00 GMT)

1 Year Iq-ai Chart

1 Year Iq-ai Chart

1 Month Iq-ai Chart

1 Month Iq-ai Chart

Your Recent History

Delayed Upgrade Clock